A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder
Phase of Trial: Phase III
Latest Information Update: 22 Jul 2019
Price : $35 *
At a glance
- Drugs Rapastinel (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Allergan
- 17 Jul 2019 Status changed from recruiting to discontinued.
- 11 Apr 2019 Planned End Date changed from 29 Feb 2020 to 22 Feb 2020.
- 11 Apr 2019 Planned primary completion date changed from 29 Feb 2020 to 22 Feb 2020.